Previous Page  11 / 38 Next Page
Information
Show Menu
Previous Page 11 / 38 Next Page
Page Background

Phase III CHAARTED Trial Long-term Follow-up:

High-Volume vs Low-Volume Disease

Median follow-up of 53.7 mos in patients with metastatic hormone-sensitive prostate cancer randomized to

ADT + docetaxel vs ADT alone (N = 790)

High-Volume Disease

Low-Volume Disease

Kyriakopoulos CE, et al. J Clin Oncol. 2018;36:1080-1087.